세계의 내시경 역행 췌담관 조영장치 시장 : 제품 유형, 기술, 용도, 최종 사용자, 지역별 세계 분석 예측(-2030년)

According to Stratistics MRC, the Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market is accounted for $1628.6 million in 2024 and is expected to reach $2627.7 million by 2030 growing at a CAGR of 8.3% during the forecast period. Endoscopic Retrograde Cholangiopancreatography (ERCP) devices are specialist medical equipment used to perform diagnostic and therapeutic treatments on the bile and pancreatic channels. Endoscopy and fluoroscopy are combined in ERCP to view and treat malignancies, strictures, and bile duct stones. A flexible endoscope is inserted through the mouth into the duodenum during the surgery. There, specialized tools such as biopsy forceps, dilators, stents, and catheters are used to clear blockages, put stents, or take tissue samples. Because they provide highly accurate, minimally invasive solutions, ERCP devices are essential for the diagnosis and treatment of pancreatic and biliary disorders.

According to the National Cancer Database, 68.5% of pancreatic cancer diagnoses in the United States are made in people over 65 years old.

Market Dynamics:

Driver:

Increasing Prevalence of Biliary and Pancreatic Disorders

The growing prevalence of biliary and pancreatic illnesses, such as gallstones, bile duct strictures, and pancreatitis, pushes up demand for Endoscopic Retrograde Cholangiopancreatography (ERCP) equipment. Effective management of these disorders depends on precise diagnosis and treatment, which makes ERCP procedures crucial. The growing number of instances, especially in older populations, encourages the use of ERCP devices and propels market expansion. The market is further expanded by ERCP's minimally invasive treatments and early identification, which enhance patient outcomes.

Restraint:

High Cost of ERCP Procedures and Devices

The high cost of ERCP procedures and equipment stifles market expansion, especially in low- and middle-income countries with restricted healthcare resources. The necessity for specialist personnel, high equipment costs, and procedural expenses may discourage hospitals and clinics from implementing ERCP technology. Further impeding the broad adoption of ERCP devices despite their therapeutic benefits are insurance coverage and payment issues, which can limit patient access to these cutting-edge procedures.

Opportunity:

Advancements in Minimally Invasive Procedures

Advances in minimally invasive techniques have a substantial impact on the ERCP device market by improving treatment precision and safety. Improved endoscopic imaging, more compact and flexible devices, and sophisticated biopsy instruments are examples of innovations that allow for better therapy results and diagnostics while shortening recuperation periods for patients. ERCP devices are becoming more and more in demand as patients choose less intrusive alternatives to standard surgery. These developments also increase treatment options, decrease problems, and streamline procedures, which support the market's growth.

Threat:

Risk of Complications

The risk of complications, such as pancreatitis, bleeding, or infections, prevents widespread use of ERCP devices. Particularly in high-risk situations, these possible hazards can discourage patients from choosing ERCP procedures and medical professionals from endorsing them. Additionally, as not all facilities may be prepared to carry out such sophisticated procedures safely; the requirement for highly qualified experts to reduce difficulties can raise costs and hinder market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Endoscopic Retrograde Cholangiopancreatography (ERCP) devices market, leading to delays and cancellations of elective procedures due to healthcare system strain. This resulted in reduced demand for ERCP devices. However, as healthcare systems recover, the market is expected to rebound with increased focus on minimally invasive diagnostic and therapeutic procedures, particularly for gastrointestinal and biliary disorders.

The biopsy forceps segment is expected to be the largest during the forecast period

The biopsy forceps segment is expected to be the largest during the forecast period because there is a growing need for precise diagnostic techniques for pancreatic and biliary disorders. During ERCP, biopsy forceps make it possible to take tissue samples, which aids in the early diagnosis of strictures, cancer, and other anomalies. The use of biopsy forceps is increased by the growing incidence of gastrointestinal disorders and improvements in minimally invasive procedures. Improved safety and accuracy are two more design elements that support market expansion.

The dilators segment is expected to have the highest CAGR during the forecast period

The dilators segment is expected to have the highest CAGR during the forecast period owing to the rising prevalence of biliary problems, advances in minimally invasive surgical techniques, and the increased desire for precise and effective procedures. In order to ensure smoother endoscope transit, dilators are necessary to dilate the strictures in the pancreatic and bile ducts. The market for ERCP devices is expanding as a result of technological advancements such disposable, ergonomic designs, and enhanced safety features that encourage the use of dilators.

Region with largest share:

North America is anticipated to hold the largest market share during the forecast period because biliary tract conditions like pancreatitis, cholangiocarcinoma, and gallstones are becoming more common. Treatment accuracy and patient outcomes are being improved by technological developments in ERCP devices, including as enhanced imaging systems and minimally invasive treatments. Furthermore, the region's high healthcare spending, well-established healthcare infrastructure, and rising use of cutting-edge medical technology all support the rising demand for ERCP devices, which in turn propels the market's expansion.

Region with highest CAGR:

Asia Pacific is anticipated to witness the highest CAGR over the forecast period due to increasing healthcare infrastructure, rising incidences of biliary and pancreatic diseases, and a growing aging population. Advancements in ERCP technologies, such as improved imaging and minimally invasive techniques, are enhancing diagnostic and therapeutic capabilities. Additionally, the region's expanding healthcare access, rising medical tourism and adoption of advanced medical devices are boosting the demand for ERCP devices, fueling market growth in Asia Pacific.

Key players in the market

Some of the key players in Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market include AMBU, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, CONMED Corporation, Cook Group, FUJIFILM Holdings Corporation, Hobbs Medical, Inc., HOYA Group, Karl Storz SE & Co. KG, Medi-Globe GmbH, Medline Industries, Inc., Medtronic PLC, Olympus Corporation, Streis PLC, Stryker Corporation, Taewoong Medical Co., Ltd. and Telemed System, Inc.

Key Developments:

In September 2024, Medtronic expanded AiBLE spine surgery ecosystem with new technologies and Siemens Healthineers partnership.

In April 2024, Medtronic plc announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO(TM), the latest generation software for the GI Genius(TM) intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

In December 2023, Medtronic plc announced that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, to offer continued innovation and scalable healthcare advancements for patients and caregivers globally.

Products Covered:

• Endotherapy Devices
• Endoscopes
• Imaging Devices
• Sphincterotomes
• Stents
• Balloon Catheters
• Biopsy Forceps
• Guidewires
• Dilators
• Other Products

Types Covered:

• Conventional ERCP
• Single-Operator ERCP
• Laparoscopic ERCP
• Endoscopic Ultrasound (EUS)-Guided ERCP
• Other Types

Technologies Covered:

• Advanced Imaging Systems
• Robotic-Assisted ERCP
• Integration with AI and Machine Learning
• Other Technologies

Applications Covered:

• Diagnostic ERCP
• Therapeutic ERCP
• Other Applications

End Users Covered:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research and Academic Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Product

• 5.1 Introduction
• 5.2 Endotherapy Devices
• 5.3 Endoscopes
• 5.4 Imaging Devices
• 5.5 Sphincterotomes
• 5.6 Stents
• 5.7 Balloon Catheters
• 5.8 Biopsy Forceps
• 5.9 Guidewires
• 5.10 Dilators
• 5.11 Other Products

6 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Type

• 6.1 Introduction
• 6.2 Conventional ERCP
• 6.3 Single-Operator ERCP
• 6.4 Laparoscopic ERCP
• 6.5 Endoscopic Ultrasound (EUS)-Guided ERCP
• 6.6 Other Types

7 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Technology

• 7.1 Introduction
• 7.2 Advanced Imaging Systems
• 7.3 Robotic-Assisted ERCP
• 7.4 Integration with AI and Machine Learning
• 7.5 Other Technologies

8 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Application

• 8.1 Introduction
• 8.2 Diagnostic ERCP
  • 8.2.1 Cholangiocarcinoma
  • 8.2.2 Pancreatitis
  • 8.2.3 Gallstones
  • 8.2.4 Biliary Strictures
• 8.3 Therapeutic ERCP
  • 8.3.1 Stone Extraction
  • 8.3.2 Stent Placement
  • 8.3.3 Sphincterotomy
  • 8.3.4 Dilation of Strictures
  • 8.3.5 Drainage of Infected Bile
• 8.4 Other Applications

9 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Specialty Clinics
• 9.4 Ambulatory Surgical Centers
• 9.5 Research and Academic Institutions
• 9.6 Other End Users

10 Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 AMBU, Inc.
• 12.2 B. Braun Melsungen AG
• 12.3 Boston Scientific Corporation
• 12.4 CONMED Corporation
• 12.5 Cook Group
• 12.6 FUJIFILM Holdings Corporation
• 12.7 Hobbs Medical, Inc.
• 12.8 HOYA Group
• 12.9 Karl Storz SE & Co. KG
• 12.10 Medi-Globe GmbH
• 12.11 Medline Industries, Inc.
• 12.12 Medtronic PLC
• 12.13 Olympus Corporation
• 12.14 Streis PLC
• 12.15 Stryker Corporation
• 12.16 Taewoong Medical Co., Ltd.
• 12.17 Telemed System, Inc.